Angiopoietin Balance in Septic Shock Patients With Acute Kidney Injury: Effects of Direct Hemoperfusion With Polymyxin B‐Immobilized Fiber. Issue 4 (August 2016)

• Record Type: Journal Article
• Authors: Ebihara, Itaru; Hirayama, Kouichi; Nagai, Miho; Shiina, Eri; Koda, Megumi; Gunji, Masanobu; Okubo, Yuki; Sato, Chihiro; Usui, Joichi; Yamagata, Kunihiro; Kobayashi, Masaki
• Other Names: Nomura Kyoichi guestEditor.
• Is Part Of: Therapeutic apheresis and dialysis. Volume 20:Issue 4(2016)
• Page Start: 368
• Page End: 375
• Publication Date: 2016-08
• Subjects: Acute kidney injury -- Angiopoietin -- Continuous renal replacement therapy -- Direct hemoperfusion, Polymyxin B‐immobilized fiber column -- Sepsis; Hemapheresis -- Periodicals; Dialysis -- Periodicals; Blood Component Removal -- Periodicals; Renal Dialysis -- Periodicals; Hémaphérèse -- Périodiques; Dialyse -- Périodiques; Sang -- Collecte et conservation -- Périodiques; 616
• DOI: 10.1111/1744-9987.12468
• Languages: English
• ISSNs: 1744-9979

Abstract

Abstract: Acute kidney injury (AKI) occurs in approximately 50% of patients in septic shock, and mortality from septic AKI is extremely high. Angiopoietin levels may play a role in the pathogenesis of vascular permeability. It was reported that direct hemoperfusion with a polymyxin B‐immobilized fiber column (DHP‐PMX) therapy ameliorates the angiopoietin balance in patients with sepsis. Although dysregulated angiopoietin balance in sepsis has been demonstrated, mechanisms underlying the development of AKI in sepsis have not been identified. We investigated angiopoietin levels in septic patients with/without AKI treated with DHP‐PMX therapy. We used an enzyme‐linked immunoassay to measure serum angiopoietin‐1 and ‐2 levels in 38 septic shock patients treated with DHP‐PMX. The renal function of all patients was normal for less than 3 months. Twenty‐seven of the patients were diagnosed with AKI. The angiopoietin‐1 level of the AKI group was significantly lower than that of the non‐AKI group at the initiation of DHP‐PMX therapy, but there was no significant difference between the two groups at the end of DHP‐PMX therapy. In the AKI group with recovery, the mean angiopoietin‐1 level at the end of DHP‐PMX therapy was significantly elevated compared to the level before DHP‐PMX therapy, and the mean angiopoietin‐2 level at the end of DHP‐PMX therapy was significantly decreased compared to the level before DHP‐PMX therapy. These results suggest that angiopoietins may play a role in the pathogenesis of AKI and that DHP‐PMX therapy may ameliorate the angiopoietin balance in AKI patients with sepsis.